Value of montelukast as a potential treatment of post-COVID-19 persistent cough: a non-randomized controlled pilot study
The Egyptian Journal of Bronchology
; 16(1), 2022.
Article
in English
| EuropePMC | ID: covidwho-2034205
ABSTRACT
Background This pilot study included 68 cases with post-COVID-19 persistent cough (> 8 weeks), randomly allocated into two groups;intervention group (32 patients) received standard cough therapy, and montelukast 10 mg/day for 14 days and control group (36 patients) received only cough sedatives. Results We found a significant improvement in the number of cough paroxysms/day, cough severity visual analog scale, cough severity index and cough quality of life, shorter duration improvement, and minimal side effects in the interventional group. Conclusions We suggest that montelukast may be effective to reduce the duration and severity of the persistent post-COVID-19 cough and further improve quality of life.
Search on Google
Collection:
Databases of international organizations
Database:
EuropePMC
Type of study:
Experimental Studies
/
Randomized controlled trials
Topics:
Long Covid
Language:
English
Journal:
The Egyptian Journal of Bronchology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS